WTO 'expected to announce' 17-year drug patent waiver for LDCs

The World Trade Organization (WTO) is expected to announce a 17-year extension to an agreement that exempts the world’s Least Developed Countries (LDCs) from a duty to grant patents covering pharmaceutical drugs, an activist group has claimed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

WTO fails to strike deal to waive COVID-19 IP

20 October 2020 Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.

Africa

WTO confirms 17-year extension to LDC patent waiver

6 November 2015 The World Trade Organization has granted permission for the world’s Least Developed Countries to be exempt from administering and enforcing patents directed to pharmaceutical drugs.

More features

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

WTO 'expected to announce' 17-year drug patent waiver for LDCs

More on this story

Editor's picks

Editor's picks

More features